This article was originally published in The Tan Sheet
Combat Meth Act cosponsor Sen. Dianne Feinstein (D-Calif.) joined other Senate Democrats and several Republicans in voting against cloture for the Patriot Act Dec. 16. Cloture was not reached as the final vote stood at 52-47, eight votes short of the 60 that are needed. The Patriot Act now includes the anti-meth measure that would place drugs containing pseudoephedrine behind the counter, require purchasers to show ID and sign a logbook, and set a purchase limit of 9 g/month. The version of the Patriot Act containing the new provisions passed the House Dec. 14 by a vote of 251-174. In the Senate, debate will continue until the Senate recesses for the holidays. If reauthorization of the Patriot Act does not occur before its expiration Dec. 31, it is unsure whether supporters of the Meth Act will attempt to include the legislation in another measure or pass it as a stand-alone bill, according to Feinstein...
You may also be interested in...
Experts including renowned virologist Peter Piot, FDA’s Peter Marks and CEPI’s Richard Hatchett discussed multiple dimensions pertaining to coronavirus variants and existing vaccines at a recent conference, noting enhanced post-deployment surveillance is underway in the US. While there’s no need to panic for every variant that emerges, equitable access to vaccines is critical to ensure that gains made over last year are not undone, they said.
It’s yet another internal deadline missed by the US agency in publishing a draft of its overhauled Quality System Regulation, which is being harmonized with international quality systems standard ISO 13485.
US FDA’s Peter Marks notes timeframe for sponsors to seek licensure at press call announcing emergency use authorization of J&J’s vaccine; Acting Commissioner Woodcock says effectiveness comparisons cannot be made between the three authorized vaccines since they have not been tested head-to-head.